Ranjeny Thomas
Professor Thomas is Professor of Rheumatology at University of Queensland, Translational Research Institute, consultant rheumatologist at Princess Alexandra Hospital, fellow of the Australian Academy of Health and Medical Sciences and member of the Order of Australia. She has founded two spin-off companies Dendright (2006-2021), and Liperate in 2022. Liperate recently opened a trial of a liposome-based tolerance immunotherapy for type 1 diabetes. Ranjeny and her team were recently awarded a MRFF Frontiers grant towards the moonshot goal of a cure for rheumatoid arthritis.
Abstracts this author is presenting:
